News | Prostate Cancer | August 20, 2015

ScanMed Brings Prostate/Pelvic MRI Coil to the Masses

CEO discusses wearable diagnostic coil on Omaha’s CBS Action News 3

Scanmed, prostate/pelvic MRI coil, Omaha, CBS Action News 3, masses

August 20, 2015 — ScanMed LLC CEO Randall Jones, Ph.D., MBA, introduced the prostate/pelvic magnetic resonance imaging (MRI) coil dedicated to prostate cancer detection on Omaha's CBS Action News 3 segment "The Morning Blend."

The landscape of prostate cancer awareness, detection and diagnosis is rapidly changing. ScanMed introduces solution-based MRI coils to the market as well as provides MRI coil repair, refurbishment, engineering, manufacturing, and online coil commerce services.

Jones saw the opportunity to improve prostate cancer detection in 2011, and dedicated his research and design team to the creation of the Prostate/Pelvic Coil. His main goal was to make affordable, non-invasive diagnostic options available to the masses, as he explained to "The Morning Blend" team Mike DiGiacomo and Mary Nelson.

Jones informed the interviewers that the only technology available has been general torso coils, which don't have enough sensitivity to detect cancers, and the endorectal probe, an invasive coil that has given male patients considerable pause (or denial) when it comes to their diagnostic options. Jones believes that this wearable MRI coil will rapidly change this paradigm.

Jones recommends that patients 40+ years old get their prostate specific antigen (PSA) test, as it can be a valid early-warning indicator. If the PSA indicates anything out of the ordinary, he then recommends looking at procedures like MRI instead of turning immediately to a "blind" biopsy, which produces approximately 50 percent false negative results and can cause damage to the prostate organ.

The key to success is the early detection that the Prostate/Pelvic Coil can provide in conjunction with advanced MRI techniques. Jones points out that in terms of later detection, typically the only treatment option presented is total removal of the organ. This typically results in incontinence, impotence or both.

For more information: www.scanmed.com

Related Content

Toshiba Showcases MRI Workflow Enhancements at RSNA 2017
News | Magnetic Resonance Imaging (MRI) | September 21, 2017
September 21, 2017 — Toshiba Medical will highlight its latest...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Siemens Healthineers to Showcase Magentom Vida MRI at RSNA 2017
Technology | Magnetic Resonance Imaging (MRI) | September 18, 2017
September 18, 2017 — Siemens Healthineers announced it will display the new Magnetom Vida 3T...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents
News | Contrast Media | September 12, 2017
The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted overwhelmingly...
News | Imaging | September 11, 2017
September 11, 2017 — Innovatus Imaging Corp., a newly created holding company formed by private equity firm Resilienc
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
Overlay Init